SERBIAN MYELOMA GROUP

As an independent association that consists of experts who deal with diagnostics, treatment, research and education in the field of multiple myeloma and associated plasma cell disorders, the work of SMG is based on a unique diagnostic and therapeutic principles and is a reflection of the exchange of professional experiences and intensive cooperation of participating haematological centres in Serbia. Since its founding on 24 December 2008, SMG realized intensive cooperation with similar national and international associations to exchange knowledge, experience, personnel and publications.
   SMG SCIENTIFIC PROJECTS:
SMG IN CLINICAL TRIALS


Comobidity indices in treatment of the patients with multiple myeloma
Associate Professor dr Jelena Bila, e-mail: jbila@yubc.net
Dr Jelena Jelicic, e-mail: jecajelicic@yahoo.com
- (PDF Download)


Prognostic significance of the cereblon expression in patients with multiple myeloma
Associate Professor dr Jelena Bila, e-mail: jbila@yubc.net
Dr Jelena Jelicic, e-mail: jecajelicic@yahoo.com
Dr Aleksandra Sretenović e-mail:asretenovic77@mail.com,
Dr Mila Purić e-mail: puricmila@yahoo.com


Molecular genetics mechanisms of the resistance in patients with multiple myeloma
Associate Professor dr Jelena Bila, e-mail: jbila@yubc.net
Dr Jelena Jelicic, e-mail: jecajelicic@yahoo.com
Dr Aleksandra Sretenović, e-mail:asretenovic77@mail.com
Dr Tatjana Dragišić, e-mail: dragisic.tatjana@gmail.com


ASPIRE, Onyx
(PDF Download)

Clinical Study Protocol C16021, Ixazomib, Millenium Pharmaceuticals
  (ongoing-)